Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists

Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for extended EYLEA HD dosing intervals for wet age-related macular degeneration and diabetic macular edema. The updated label allows ...

Regeneron Gets FDA OK for Extended Eylea HD Dosing

Regeneron Pharmaceuticals has won Food and Drug Administration approval of extended dosing intervals of up to every 20 weeks for its Eylea HD eye drug.
MPR

FDA Approves Extended Eylea HD Dosing Interval for wAMD, DME

The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...
Healio

FDA approves Eylea HD dosing intervals up to 5 months for wet AMD, DME

The FDA approved an extension of dosing intervals for Eylea HD in patients with diabetic macular edema and wet age-related macular degeneration, Regeneron Pharmaceuticals, Inc. announced.The approval, ...
Ophthalmology Times

FDA approves extended dosing intervals up to 20 weeks for EYLEA HD in wAMD and DME

The US Food and Drug Administration has approved the extension of dosing intervals for Regeneron’s EYLEA HD (aflibercept) up ...

Apogee Therapeutics Highlights 52-Week Zumi Data, Targets 3- to 6-Month Dosing in AD

Apogee Therapeutics (NASDAQ:APGE) outlined new 52-week maintenance data from its Phase II APECS Part A study of zumilokibart ...